The American Journal of Managed Care

FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...
Everyday Health

What to Expect When Starting Subcutaneous Immunotherapy for Cancer

Y our oncologist may prescribe immunotherapy at various points in the cancer treatment journey. Immunotherapy is known to be especially effective in treating late-stage cancer that hasn’t responded to ...
Healio

FDA approves Leqembi at-home subcutaneous injection in early Alzheimer’s

Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
Nasdaq

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Cure Today

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...
Healio

FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...